Parkinson's Disease: Genetics, Mechanisms and Therapeutics

joint with Alzheimer's Disease - From Fundamental Insights to Light at the End of the Translational Tunnel

Organizer(s): Patrick A. Lewis, Thomas Gasser and Marcel P. van der Brug

Sponsored by Curemark, LLC

Summary of Meeting:

Our understanding of the causes of Parkinson’s disease has undergone a revolution in the last twenty years, driven by advances in cellular neuroscience and molecular genetics. Identification of rare autosomal Mendelian genes causative for Parkinsonism and recent genome wide association studies have revealed novel mechanisms that underlie neuronal death. The themes emerging from these advances, especially protein aggregation, immune response and mitochondrial dysfunction, highlight the overlap with other neurodegenerative diseases such as Alzheimer’s. This meeting will cover our current state of knowledge of the global genetic architecture of Parkinson’s, how this is informing cellular and molecular approaches to the etiology of the disease, and the implications of these discoveries in patient diagnosis and development of novel treatments for Parkinson’s disease. In combination with the parallel meeting on Alzheimer’s disease, it will explore the commonalities between these two devastating disorders and discuss how recent advances in each field can be used to accelerate research.

Scholarship Deadline: November 5 2013

Discounted Abstract Deadline: November 5 2013

Abstract Deadline: December 5 2013

Discounted Registration Deadline: January 8 2014

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Bristol-Myers Squibb Company

Genentech, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Neurological Disorders and Stroke (NINDS)
Grant No. 1R13NS084618-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations